GOSH researchers receive UCL Business Award

23 Jun 2017, 12:57 p.m.

Professors Bobby Gasper and Adrian Thrasher, both members of the BRC senior management team, have been awarded the UCL Business Award, in recognition of their work on the spin-out company Orchard Therapeutics.

Orchard is a biotechnology company focused on the development and commercialization of gene therapy medicines for children with rare diseases. It was launched in May 2016 with support from UCL Business and a £21 million investment from F-Prime Capital Partners.

Orchard focusses on restoring normal gene function in immunodeficiencies, metabolic diseases and haematological disorders and builds on GOSH researchers' expertise in stem, cell and gene therapies. Read more.

Professor Gaspar is Deputy Director of the NIHR GOSH BRC and Professor Thrasher is BRC Theme Lead for Gene, Stem and Cellular Therapies.

Spotlight on our Research Co-ordinators

Meet the staff who keep clinical trials on track, ensure the data is up-to-date, that rules are followed and families get their agreed upon support.

NHS eye gene therapy restores Saffie's sight

Saffie has had her sight restored thanks to life-changing eye gene therapy for rare blindness at GOSH

£3M study led by patient voices targets pain in inflammatory arthritis

A new £3 million research programme involving Great Ormond Street Hospital and University College London researchers aims to tackle one of the largest unmet clinical needs in inflammatory arthritis – pain reduction.

GOSH joins European health leaders to shape the future of paediatric data sharing

More than 50 clinicians, data scientists, digital health innovators and industry leaders came together in Barcelona last month to tackle one of the biggest challenges in paediatric healthcare: how to share health data safely across borders to improve care